Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Case Report: Drug-Induced Lupus & ANCA-Associated Vasculitis Overlap

Mohammad A. Ursani, MD, RhMSUS, Ojas Naik, MD, Rohaan Khan & William F. Glass II, MD, PhD  |  Issue: February 2021  |  February 16, 2021

MOLEKUUL / Science Source

MOLEKUUL / Science Source

Drug-induced lupus erythe­matosus and ANCA-associated vasculitis (AAV) are both autoimmune conditions associated with the use of hydralazine, a commonly prescribed drug for hypertension and congestive heart failure. Although the pathogenesis is unknown, it is believed that hydralazine alters neutrophil and lymphocyte function and promotes exposure of antigens, leading to the development of anti-neutrophil antibodies (ANCA) and/or anti-nuclear antibodies (ANA) and ultimately triggering a systemic response.1 

These conditions are rare and typically considered to be mutually exclusive. Here, we describe a rare presentation in which hydralazine appears to be the inciting factor of a patient developing an overlap of drug-induced lupus erythematosus and AAV.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Case Report

A 75-year-old Caucasian woman with a history of hypertension was admitted for fever, periorbital edema, erythematous conjunctiva, papular lesions all over her body and a mucosal ulceration on the hard palate of her oral cavity. 

She had no reported history of Raynaud’s phenomenon, alopecia, photosensitivity, joint pain or synovitis. She denied a history of venous thromboembolism or recurrent pregnancy loss. She denied epistaxis and new-onset neuropathy. She had no recent changes to her medication, but had been using hydralazine 25 mg twice daily as the drug of choice for hypertension for more than a year. Her personal surgical and family history were otherwise unremarkable. 

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

During her hospitalization, infection was ruled out and ocular findings were determined to be consistent with episcleritis. 

Laboratory data revealed proteinuria and hematuria on initial urinalysis. Serum creatinine was elevated from her normal baseline at 1.44 mg/dL (normal: 0.50–1.40 mg/dL) with a BUN (blood urea nitrogen) level of 39 mg/dL (normal: 7–22 mg/dL). Her urine creatinine was 86.8 mg/dL and urine protein was 335 mg/dL, with a ratio of 3.86. 

The complete blood count revealed leukopenia 3.6 cells/µl (normal: 4.5–10 cells/µl), and lymphopenia 10.1% (normal: 20–40%). An autoimmune evaluation was remarkable for ANA (1:640 speckled), anti-double-stranded DNA antibodies (1:10), myeloperoxidase (MPO) ANCA, and P-ANCA 1:320. Her C3 level was 69 mg/dL (normal: 88–201 mg/dL) and C4 was 10 mg/dL (normal: 16–44 mg/dL). Her C-reactive protein was elevated at 214 mg/L (<2.9 mg/L), as was the sedimentation rate at >100 mm/Hr (normal: 0–20 mm/hr). Her anti-histone immunoglobulin (Ig) G was 5.0 (normal: 0.0–0.9 units). Anti-Smith, anti-RNP and anti-SSA/SSB antibodies were negative. Antiphospholipid antibodies were negative. Cryoglobulin, anti-glomerular basement membrane antibodies and proteinase-3 (PR3) ANCA were undetectable.

CT imaging revealed stenosis at the left subclavian artery, multiple sub-centimeter pulmonary nodules, cardiomegaly and trace pericardial and pleural effusions. Additionally, incidental findings of hepatic and renal cysts were noted. 

Page: 1 2 3 | Single Page
Share: 

Filed under:ConditionsSystemic Lupus ErythematosusVasculitis Tagged with:ANCA-Associated Vasculitiscase reporthydralazine

Related Articles

    Case Report: Hydralazine-Induced ANCA-Associated Vasculitis

    February 16, 2021

    Hydralazine has been in use as a treatment for hypertension, most notably in heart failure patients, since 1951.1 The drug is a known cause of autoimmune disease, most specifically hydralazine-induced lupus.  Hydralazine-induced lupus occurs in 7–13% of those taking the medication.2-4 It often presents with constitutional symptoms, arthritis/arthralgias, cutaneous lesions, sero­sitis, myalgias and/or hepatomegaly. Features…

    Top Research in ANCA-Associated Vasculitis Presented at ACR Convergence 2023

    November 21, 2023

    SAN DIEGO—Vasculitis expert and former editor of The Rheumatologist, Dr. Philip Seo gives us his picks for the 10 most important abstracts in ANCA-associated vasculitis to come out of ACR Convergence 2023.

    Case Report: Drug-Induced Lupus

    September 14, 2021

    The incidence of drug-induced lupus continues to rise as clinicians expand their therapeutic armamentarium. An estimated 15,000–30,000 cases of drug-induced lupus occur every year in the U.S. alone.1 It is a well-known, but rare, complication of commonly used medications, such as anti-hypertensive, anti-arrhythmic and anti-epileptic drugs, as well as biologic and immune checkpoint therapies.2,3 The…

    Laboratory Testing for Diagnosis, Management of Patients with Rheumatic Disease

    December 1, 2014

    A review of data on antinuclear antibodies and tests for rheumatoid arthritis

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences